绝经期激素治疗与阿尔茨海默病神经病理的关联
本研究利用NACC和ADNI两个大型队列,分析50岁以上女性使用雌激素-only MHT与AD神经病理、临床及生物标志物结局的关联。结果显示MHT使用者尸检AD病理 odds 显著降低(OR 0.65),临床痴呆诊断和记忆/功能下降 odds 也显著降低。结论提示MHT可能与痴呆病程中的保护效应相关,但无法确立因果。
要点
- MHT使用者尸检AD病理 odds 显著低于非使用者(OR 0.65, 95%CI 0.48-0.88)。
- MHT使用与临床痴呆诊断 odds 降低相关(OR 0.61, 95%CI 0.55-0.67)。
- MHT使用与血浆和CSF淀粉样蛋白病理负荷降低相关。
核心结论
- 在兩個大型女性队列中,晚年使用雌激素-only MHT与AD相关神经病理和临床结局存在小幅但显著的关联。
- 结果不能确立因果,但提示MHT在痴呆病程中可能具有保护效应。
研究设计与样本
- 队列研究,使用NACC和ADNI两个独立大型数据集。
- 纳入50岁及以上女性,自我报告使用雌激素-only MHT或无MHT使用。
- NACC神经病理数据:MHT使用者258例(死亡平均年龄81.9,SD=19.5),非使用者2701例(死亡平均年龄82.2,SD=11.0)。
- ADNI队列:MHT使用者110例(平均年龄76.5,SD=7.5),非使用者1948例(平均年龄73.2,SD=8.9)。
主要发现
- 尸检AD病理增加的主要结局 odds 在MHT使用者中显著降低(OR 0.65, 95%CI 0.48-0.88, p=0.005)。
- MHT使用与血浆淀粉样蛋白病理负荷显著降低相关(β=0.44, 95%CI 0.16-0.73, p=0.0025)。
- MHT使用与CSF淀粉样蛋白病理负荷显著降低相关(β=0.07, 95%CI 0.002-0.13, p=0.030)。
- MHT使用与临床痴呆诊断 odds 显著降低相关(OR 0.61, 95%CI 0.55-0.67, p<0.0001)。
- MHT使用与记忆/功能下降症状 odds 显著降低相关(OR 0.67, 95%CI 0.61-0.74, p<0.0001)。
临床怎么用
- 对于50岁以上女性,询问绝经期激素治疗使用史可能有助于痴呆风险评估。
- 雌激素-only MHT使用与AD病理和临床痴呆 odds 降低相关,但需结合个体情况谨慎解读。
局限性
- 研究为回顾性设计,不能确立因果关系。
- 结果因回顾性性质而普遍性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Although evidence suggests that the neurophysiologic impact of estrogen decline during menopause may contribute to increased risk of Alzheimer disease (AD) in women, the effect of menopausal hormonal therapy (MHT) on AD risk requires further study. We sought to examine the associations between MHT use and neuropathologic, clinical, and imaging/fluid biomarker outcomes. METHODS: In this cohort study, we tested the association between estrogen-only MHT use and dementia outcomes in female participants using 2 independent, large-scale data sets: National Alzheimer's Coordinating Center (NACC) and Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants included women 50 years and older with self-reported use of estrogen-only MHT or no self-reported use of MHT. Clinical, imaging/fluid biomarker, and neuropathologic outcomes were examined. Research was performed at academic medical centers. RESULTS: Neuropathologic data were collected from NACC for 258 MHT users (mean age of death = 81.9, SD = 19.5) and 2,701 non-MHT users (mean age of death = 82.2, SD = 11.0). The ADNI cohort included 110 MHT users (mean age = 76.5, SD = 7.5) and 1,948 non-MHT users (mean age = 73.2, SD = 8.9). The odds of increased AD pathology on autopsy (primary outcome) were significantly decreased in MHT users relative to nonusers (odds ratio [OR] 0.65, 95% CI 0.48-0.88, p = 0.005). MHT use was associated with secondary outcomes including significantly decreased amyloid pathologic load assessed through plasma (β = 0.44, 95% CI 0.16-0.73, p = 0.0025) and CSF (β = 0.07, 95% CI 0.002-0.13, p = 0.030). MHT use was associated with significantly lower odds of clinical dementia diagnoses (OR 0.61, 95% CI 0.55-0.67, p < 0.0001) and lower odds of symptoms of memory/functional decline (OR 0.67, 95% CI 0.61-0.74, p < 0.0001). DISCUSSION: Our findings demonstrate small but significant associations between MHT use during later life and a range of AD-related neuropathologic and clinical outcomes in 2 large cohorts of female participants. Although our results do not address causality and have limited generalizability due to the retrospective nature of the study, they suggest a protective effect of MHT use in the dementia course.
引用
- Bruno J, Shaw JS, Hosseini SMH, et al. Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology. Neurology. 2026. PMID: 42585606. doi:10.1212/WNL.0000000000218413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。